甲地孕酮治疗子宫内膜不典型增生中Ang-1、Ang-2及受体Tie-2表达  

The expression of Ang-1,Ang-2 and Tie-2 in the endometrial atypical hyperplasia with treatment of megestrol acetate

作　　者：崔青[1] 赵文杰[2] 马华刚[2] 王文双[1] 孙理兰[2] 

机构地区：[1]烟台市毓璜顶医院产科,山东省264000 [2]潍坊市人民医院生殖医学科

出　　处：《中华临床医师杂志（电子版）》2014年第22期59-62,共4页Chinese Journal of Clinicians(Electronic Edition)

摘　　要：目的检测子宫内膜不典型增生患者应用甲地孕酮治疗前、治疗后Ang-1、Ang-2及受体Tie-2的表达水平,探讨Angs/Tie-2信号途径在甲地孕酮治疗子宫内膜不典型增生中的作用。方法选取2011年1月至2013年8月,行病理组织活检确诊为子宫内膜不典型增生的患者26例作为试验组,同时间确诊为正常子宫内膜患者19例作为对照组,试验组常规应用甲地孕酮3个月,Western blot和RT-PCR检测对照组、试验组用药前、用药后Ang-1、Ang-2以及Tie-2的表达。结果 26例试验组的患者中,14例显效,9例有效,总有效率88.46%。与对照组相比,Western blot与RT-PCR的结果均显示,子宫内膜不典型增生患者,Ang-1呈低表达,Ang-2、Tie-2呈高表达。应用甲地孕酮治疗后,Ang-1表达增高,而Ang-2、Tie-2表达降低,差异有统计学意义(P<0.05)。结论甲地孕酮是治疗子宫内膜不典型增生的有效药物,其治疗效果可能是通过Angs/Tie-2信号途径来实现的。Objective To study the expression of angiopoietin（Ang）-1, Ang-2 and their receptor andothelium specific receptor tyrosine kinase （Tie）-2 in the treatment of megestrol acetate in endometrial atypical hyperplasia.Methods From January 2011 to August 2013, 26 cases of the endometrial atypical hyperplasia as experimental group and 19 cases of the normal endometrium as control group, were included in the study. All the experimental group’ patients were treated with megestrol acetate, the expression of Ang-1, Ang-2, Tie-2 were detected among the control group and the experimental group of pre-administration and post-administration.Results In the experimental group, 14 cases had marked effect, 9 were effective and total efficiency was 88.46%. Compared with the control group, Western blot and RT-PCR results were displayed that Ang-1 is low-expression while Ang-2 and Tie-2 has higher expression in patients with atypical endometrial hyperplasia. After application of megestrol acetate treatment, Ang-1 expression increased while Ang-2 and Tie-2 expression decreased significantly（P〈0.05）. Conclusion Megestrol acetate is an effective drug in curing atypical hyperplasia, and it may be achieved by Angs/Tie-2 signal pathway.

关 键 词：甲地孕酮 子宫内膜增生 血管生成素1 血管生成素2 受体 TIE-1 

分 类 号：R737.33[医药卫生—肿瘤]